Nastech Plans Phase II For Teriparatide Nasal Spray In Q1 2008 After P&G Returns Rights
This article was originally published in The Pink Sheet Daily
Executive Summary
Procter & Gamble notified the company of its decision to terminate a development deal for the teriparatide nasal spray for osteoporosis.
You may also be interested in...
Lilly Licenses Hormone Patch For Osteoporosis
Lilly Licenses Hormone Patch For Osteoporosis
Lilly Licenses Hormone Patch For Osteoporosis
Lilly Licenses Hormone Patch For Osteoporosis
Renamed Nastech Turns To RNAi
Company to divest intranasal program rather than spin out.